|
AU2016201475A1
|
|
Pharmaceutical formulation
|
|
AU2013205466A1
|
|
Solid dose feeder and operating method thereof
|
|
AU2013202441A1
|
|
Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
|
|
AU2013202526A1
|
|
A dosage form containing two or more active pharmaceutical ingredients in different physical forms
|
|
AU2013202529A1
|
|
Pharmaceutical formulation
|
|
EP2306998A1
|
|
Pharmaceutical formulation
|
|
US2011206770A1
|
|
Atovaquone with a particle size diameter range (d90) of greater than 3 microns to about 10 microns
|
|
WO2009092129A1
|
|
Delayed release pharmaceutical composition of duloxetine
|
|
AU2008314489A1
|
|
Controlled-release pharmaceutical formulation
|
|
NZ602934A
|
|
Controlled-release pharmaceutical formulation
|
|
ZA200808569B
|
|
Controlled release formulation comprising uncoated discrete unit(s) and an extended release matrix
|
|
WO2009026621A1
|
|
Pharmaceutical compound & composition
|
|
AU2008213744A1
|
|
A dosage form containing two or more active pharmaceutical ingredients in different physical forms
|
|
AU2007335191A1
|
|
Pharmaceutical compound and composition
|
|
AU2007335192A1
|
|
Pharmaceutical composition
|
|
WO2008000040A1
|
|
A stabilised composition comprising ace inhibitors
|
|
NZ703464A
|
|
Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
|
|
CA2648495A1
|
|
Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
|
|
AU2007242062A1
|
|
Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
|
|
CA2628716A1
|
|
Process to control particle size
|
